phenylalanine butyl ester | 120109-15-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: phenylalanine butyl ester
• 英文别名: Butyl D-phenylalaninate；butyl (2R)-2-amino-3-phenylpropanoate
• CAS: 120109-15-1
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: VSFDFIPJWOBYLZ-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  D-苯丙氨酸 生成 phenylalanine butyl ester
  参考文献：
  名称：

  YAMAMOTO, YOSHINORI;ITO, WATARU, TETRAHEDRON, 44,(1988) N 17, C. 5415-5423

  摘要：

  DOI：

文献信息

• Studies on the reaction of α-imino esters with organometallic compounds
  作者：Yoshinori Yamamoto、Wataru Ito

  DOI：10.1016/s0040-4020(01)86047-6

  日期：1988.1

  other organometallic reagents such as Mg. Al, Cu, Tl, and B derivatives reacted at the nitrogen atom. Use of the (S)-amine as a chiral auxiliary of 2 created the R chirality at the imino carbon. Very high chiral Induction was realized In the reaction of prenylzinc reagent wlih α-imino 8-(-)phenylmenthyl ester (10). The reaction of 2 with heteroatom substituted allylic organometalic compounds (15) gave

  苄基锌试剂仅与α-亚氨基酯（2）在α-碳上反应，其他有机金属试剂（如Mg）也可与之反应。Al，Cu，Tl和B衍生物在氮原子上反应。（S）-胺作为2的手性助剂的使用在亚氨基碳上产生R手性。在异戊二烯锌试剂与α-亚氨基8-（-）苯基薄荷基酯（10）的反应中实现了非常高的手性诱导。2与杂原子取代的烯丙基有机金属化合物（15）反应，得到相应的α-异位取代的氨基酸衍生物（16）。同样，与相应的T1，Al和B试剂相比，烯丙基锌试剂以更高的产率得到加合物。
• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Marsault Eric

  公开号：US20090221689A1

  公开（公告）日：2009-09-03

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素释放肽受体（GHS-R1a及其亚型，同工型和变异体）的选择性调节剂。本文还描述了合成新型化合物的方法。这些化合物可用作生长激素释放肽受体的激动剂，并作为治疗和预防一系列医疗状况的药物，包括但不限于代谢和/或内分泌紊乱，胃肠道疾病，心血管疾病，肥胖和肥胖相关疾病，中枢神经系统疾病，遗传性疾病，高增殖性疾病和炎症性疾病。
• ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Cheng Xiaoqin

  公开号：US20090291922A1

  公开（公告）日：2009-11-26

  Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 and R X2 are independently R X ; Y 1 is ═O, —O(R X ), ═S, —N(R X ), —N(O)(R X ), —N(OR X ), —N(O)(OR X ), or —N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently —H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is —H, —F, —Cl, —Br, —I, —CF 3 , —CN, N 3 , —NO 2 , or —OR 4 ; R 3b is ═O, —O(R 4 ), ═S, —N(R 4 ), —N(O)(R 4 ), —N(OR 4 ), —N(O)(OR 4 ), or —N(N(R 4 )(R 4 )); R 3c is —R 4 , —N(R 4 )(R 4 ), —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —S(O)(OR 4 ), —S(O) 2 (OR 4 ), —OC(R 3b )R 4 , —OC(R 3b )OR 4 , —OC(R 3b )(N(R 4 )(R 4 )), —SC(R 3b )R 4 , —SC(R 3b )OR 4 , —SC(R 3b )(N(R 4 )(R 4 )), —N(R 4 )C(R 3b )R 4 , —N(R 4 )C(R 3b )OR 4 , —N(R 4 )C(R 3b ) (N(R 4 )(R 4 )), W 3 or —R 5 W 3 ; R 3d is —C(R 3b )R 4 , —C(R 3b )OR 4 , —C(R 3b )W 3 , —C(R 3b )OW 3 or —C(R 3b )(N(R 4 )(R 4 )); R 4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , —C(R 3b )R 6 , —C(R 3b )W 5 , —SO M2 R 6 , or —SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof.

  本发明涉及一种公式I的化合物和组合物，用作抗增殖剂，特别是抗HPV，其中：Y1A和Y1B独立地为Y1;RX1和RX2独立地为RX；Y1为═O，—O（RX），═S，—N（RX），—N（O）（RX），—N（ORX），—N（O）（ORX）或—N（N（RX）（RX））；RX独立地为R1，R2，R4，W3或保护基；R1独立地为—H或1至18个碳原子的烷基；R2独立地为R3或R4，其中每个R4独立地用0至3个R3基替代或在一个碳原子上结合，两个R2基形成3至8个碳原子的环，并且该环可以用0至3个R3基替代；R3为R3a，R3b，R3c或R3d，但当R3与杂原子结合时，则R3为R3c或R3d；R3a为—H，—F，—Cl，—Br，—I，—CF3，—CN，N3，—NO2或—OR4；R3b为═O，—O（R4），═S，—N（R4），—N（O）（R4），—N（OR4），—N（O）（OR4）或—N（N（R4）（R4））；R3c为—R4，—N（R4）（R4），—SR4，—S（O）R4，—S（O）2R4，—S（O）（OR4），—S（O）2（OR4），—OC（R3b）R4，—OC（R3b）OR4，—OC（R3b）（N（R4）（R4）），—SC（R3b）R4，—SC（R3b）OR4，—SC（R3b）（N（R4）（R4）），—N（R4）C（R3b）R4，—N（R4）C（R3b）OR4，—N（R4）C（R3b）（N（R4）（R4）），W3或—R5W3；R3d为—C（R3b）R4，—C（R3b）OR4，—C（R3b）W3，—C（R3b）OW3或—C（R3b）（N（R4）（R4））；R4为—H，或1至18个碳原子的烷基，2至18个碳原子的烯基或2至18个碳原子的炔基；R5为1至18个碳原子的亚烷基，2至18个碳原子的烯亚烷基或2至18个碳原子的炔亚烷基；W3为W4或W5；W4为R6，—C（R3b）R6，—C（R3b）W5，—SOM2R6或—SOM2W5，其中R6为R4，其中每个R4用0至3个R3基替代；W5为碳环或杂环，其中W5独立地用0至3个R2基替代；M2为0、1或2；以及其药学上可接受的盐。
• MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
  申请人：TRANZYME PHARMA INC.

  公开号：US20130211045A1

  公开（公告）日：2013-08-15

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新型构象定义的大环化合物，已经被证明是生长激素分泌肽受体（GHS-R1a和其亚型、同工异构体和变异体）的选择性调节剂。本文还描述了合成这些新化合物的方法。这些化合物可用作生长激素分泌肽受体的激动剂，以及用于治疗和预防一系列医学疾病，包括但不限于代谢和/或内分泌紊乱、胃肠道疾病、心血管疾病、肥胖和肥胖相关疾病、中枢神经系统疾病、遗传疾病、过度增生性疾病和炎症性疾病。
• YAMAMOTO, YOSHINORI;ITO, WATARU, TETRAHEDRON, 44,(1988) N 17, C. 5415-5423
  作者：YAMAMOTO, YOSHINORI、ITO, WATARU

  DOI：——

  日期：——